Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Altiris Therapeutics

Latest From Altiris Therapeutics

Start-Up Quarterly Statistics, Q4 2007

Start-Up analyzes fundraising and alliances among start-ups in the biopharmaceutical, medical device and in vitro diagnostics segments from October through December 2007. Data is derived from Windhover’s Strategic Transactions Database.
Business Strategies Business Strategies

Pacific Horizon: Encouraging Mutations in the Venture Model

Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Metastatix Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Altiris Therapeutics
  • Senior Management
  • Carol G Gallagher, PharmD, Pres. & CEO
    Mike Natchus, PhD, VP, R&D
  • Contact Info
  • Altiris Therapeutics
    Phone: (678) 367-0720
    1860 Montreal Rd.
    Tucker, GA 30084